NO20082379L - Process for Preparation of Purified Crystalline CCI-779 - Google Patents
Process for Preparation of Purified Crystalline CCI-779Info
- Publication number
- NO20082379L NO20082379L NO20082379A NO20082379A NO20082379L NO 20082379 L NO20082379 L NO 20082379L NO 20082379 A NO20082379 A NO 20082379A NO 20082379 A NO20082379 A NO 20082379A NO 20082379 L NO20082379 L NO 20082379L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- purified crystalline
- crystalline cci
- cci
- purified
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
- 229960000235 temsirolimus Drugs 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer renset krystallinsk CCI-779 og fremgangsmåter for fremstilling av denne.The present invention provides purified crystalline CCI-779 and processes for its preparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74800605P | 2005-12-07 | 2005-12-07 | |
PCT/US2006/046444 WO2007067565A1 (en) | 2005-12-07 | 2006-12-06 | Process for the preparation of purified crystalline cci-779 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082379L true NO20082379L (en) | 2008-09-04 |
Family
ID=37891446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082379A NO20082379L (en) | 2005-12-07 | 2008-05-26 | Process for Preparation of Purified Crystalline CCI-779 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7553843B2 (en) |
EP (1) | EP1957500A1 (en) |
JP (1) | JP2009518413A (en) |
KR (1) | KR20080077618A (en) |
CN (1) | CN101321769A (en) |
AR (1) | AR058282A1 (en) |
AU (1) | AU2006322029A1 (en) |
BR (1) | BRPI0619493A2 (en) |
CA (1) | CA2630784A1 (en) |
CR (1) | CR9988A (en) |
EC (1) | ECSP088517A (en) |
GT (1) | GT200800089A (en) |
IL (1) | IL191546A0 (en) |
NO (1) | NO20082379L (en) |
PE (1) | PE20071041A1 (en) |
RU (1) | RU2008121240A (en) |
TW (1) | TW200732342A (en) |
WO (1) | WO2007067565A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011051960A2 (en) | 2009-09-25 | 2011-05-05 | Cadila Healthcare Limited | Process for the preparation of rapamycin derivatives |
CN109020995A (en) * | 2017-06-12 | 2018-12-18 | 鲁南制药集团股份有限公司 | A kind of crystal form object of tesirolimus |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358909A (en) * | 1991-02-27 | 1994-10-25 | Nippon Steel Corporation | Method of manufacturing field-emitter |
US5358908A (en) * | 1992-02-14 | 1994-10-25 | Micron Technology, Inc. | Method of creating sharp points and other features on the surface of a semiconductor substrate |
US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
DK1319008T3 (en) | 2000-09-19 | 2009-02-09 | Wyeth Corp | Water-soluble rapamycin esters |
FR2826961B1 (en) * | 2001-07-06 | 2005-09-30 | Atofina | PROCESS FOR THE PREPARATION OF (METH) ACRYLIC ANHYDRIDE |
CA2528173A1 (en) | 2003-07-16 | 2005-02-03 | Wyeth | Cci-779 isomer c |
ES2287772T3 (en) | 2003-08-07 | 2007-12-16 | Wyeth | REGIONAL ELEMENT SYNTHESIS OF CCI-779. |
SG145716A1 (en) | 2003-09-03 | 2008-09-29 | Wyeth Corp | Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same |
DE602005010228D1 (en) | 2004-04-14 | 2008-11-20 | Wyeth Corp | METHOD OF PREPARING RAPAMYCIN-42 ESTERS AND FK-506-32 ESTERS WITH DICARBOXYLIC ACID, PREPARATIONS FOR RAPAMYCIN CONJUGATES AND ANTIBODIES |
AU2005238431A1 (en) | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
JP2008517874A (en) | 2004-08-10 | 2008-05-29 | ワイス | CCI-779 derivatives and methods for their preparation |
ATE549342T1 (en) | 2004-12-20 | 2012-03-15 | Wyeth Llc | RAPAMYCIN ANALOGS AND THEIR USES IN THE TREATMENT OF PROLIFERATIVE, INFLAMMATORY AND NEUROLOGICAL DISORDERS |
EP1828203A2 (en) | 2004-12-20 | 2007-09-05 | Wyeth | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
CA2595766A1 (en) * | 2005-02-09 | 2006-08-17 | Wyeth | Cci-779 polymorph and use thereof |
CN101133066A (en) | 2005-03-02 | 2008-02-27 | 惠氏公司 | Recovery of CCI-779 from mother liquors |
CN101137659A (en) | 2005-03-07 | 2008-03-05 | 惠氏公司 | Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin |
-
2006
- 2006-12-06 BR BRPI0619493A patent/BRPI0619493A2/en not_active IP Right Cessation
- 2006-12-06 CA CA002630784A patent/CA2630784A1/en not_active Abandoned
- 2006-12-06 EP EP06839039A patent/EP1957500A1/en not_active Withdrawn
- 2006-12-06 JP JP2008544450A patent/JP2009518413A/en active Pending
- 2006-12-06 US US11/634,774 patent/US7553843B2/en not_active Expired - Fee Related
- 2006-12-06 TW TW095145388A patent/TW200732342A/en unknown
- 2006-12-06 AR ARP060105388A patent/AR058282A1/en unknown
- 2006-12-06 RU RU2008121240/04A patent/RU2008121240A/en not_active Application Discontinuation
- 2006-12-06 KR KR1020087013678A patent/KR20080077618A/en not_active Application Discontinuation
- 2006-12-06 CN CNA2006800458140A patent/CN101321769A/en not_active Withdrawn
- 2006-12-06 PE PE2006001556A patent/PE20071041A1/en not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046444 patent/WO2007067565A1/en active Application Filing
- 2006-12-06 AU AU2006322029A patent/AU2006322029A1/en not_active Abandoned
-
2008
- 2008-05-19 IL IL191546A patent/IL191546A0/en unknown
- 2008-05-19 CR CR9988A patent/CR9988A/en not_active Application Discontinuation
- 2008-05-26 NO NO20082379A patent/NO20082379L/en not_active Application Discontinuation
- 2008-06-05 GT GT200800089A patent/GT200800089A/en unknown
- 2008-06-09 EC EC2008008517A patent/ECSP088517A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101321769A (en) | 2008-12-10 |
CR9988A (en) | 2008-07-29 |
AU2006322029A1 (en) | 2007-06-14 |
TW200732342A (en) | 2007-09-01 |
ECSP088517A (en) | 2008-07-30 |
KR20080077618A (en) | 2008-08-25 |
US20070129395A1 (en) | 2007-06-07 |
GT200800089A (en) | 2008-12-04 |
AR058282A1 (en) | 2008-01-30 |
JP2009518413A (en) | 2009-05-07 |
RU2008121240A (en) | 2010-01-20 |
EP1957500A1 (en) | 2008-08-20 |
US7553843B2 (en) | 2009-06-30 |
WO2007067565A1 (en) | 2007-06-14 |
IL191546A0 (en) | 2008-12-29 |
CA2630784A1 (en) | 2007-06-14 |
PE20071041A1 (en) | 2007-12-07 |
BRPI0619493A2 (en) | 2016-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007005221A (en) | Ascomycin crystalline forms and preparation thereof. | |
NO20071050L (en) | Rapamycin polymorph II and uses thereof | |
TW200801262A (en) | Method for purifying silicon | |
TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
ATE497492T1 (en) | CLEANING MONTELUKAST | |
ATE528989T1 (en) | CRYSTALLINE SOLID RASAGILIN BASE | |
DK1836169T3 (en) | COMPOSITIONS AND PROCEDURES FOR TREATING CELL PROLIFERATION DISEASES | |
WO2007022459A3 (en) | Processes and intermediates | |
DE602006020327D1 (en) | 2-PHENOXY-N- (1,3,4-THIADIZOL-2-YL) PYRIDINE-3-AMINDER INHIBITOR FOR THE TREATMENT OF THROMBOEMBOLIC ILLNESSES | |
WO2006124713A3 (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
NO20076371L (en) | Process for the preparation of phenolic 4-biphenylylazetidin-2-ones | |
NO20063196L (en) | New fused pyrrolocarbazoles | |
ATE393764T1 (en) | POLYMORPHOUS FORMS OF VALSARTAN | |
NO20071254L (en) | Process for the preparation of irbesartan and its intermediates. | |
NO20072473L (en) | Process for the preparation of quinoline compounds and derived products | |
ATE410166T1 (en) | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES FOR THE TREATMENT OF INFERTILITY | |
NO20060535L (en) | Aztreonam-L-lysine and methods for preparing it | |
WO2006132739A3 (en) | Novel chemical compounds | |
NO20083751L (en) | Methods for the treatment of cognitive and other diseases | |
NO20073725L (en) | CCI-779 polymorph and its use | |
DK1926732T3 (en) | PROCEDURE FOR THE PREPARATION OF CARBAPENNAM RELATIONS | |
NO20073276L (en) | Method for the preparation of aminoethoxybenzyl alcohols | |
WO2010148177A3 (en) | Compounds, compositions, methods of synthesis, and methods of treatment | |
NO20091140L (en) | Process for the preparation of polyester nanocomposites | |
WO2006127458A3 (en) | Novel chemical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |